X
[{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta to Present Preliminary Phase I\/II Clinical Data on Temferon\u2122 in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta\u2019s Temferon\u2122 Shows Controlled and Targeted Interferon Expression in Preliminary Phase I\/II Clinical Data in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Phase I\/II Glioblastoma Data at ASGCT Show Temferon\u2122 Delivered Tumor-Focused Interferon Expression","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta To Present Updated Phase I\/II Data At Upcoming Scientific Congresses SNO AND ASH","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Data Presentation at AACR to Describe On-Target Biological Activity of Temferon\u2122 in Unmethylated Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta to Host Expert Fireside Chat on Immuno Gene & Cell Therapy for Treatment of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Progresses to Higher Dosing Cohort in Temferon Phase 1\/2a Clinical Trial in Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Ospedale San Raffaele","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"The European Commission Grants Orphan Drug Designation to Temferon for Treatment of Glioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Genenta Science","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ITALY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]
Find Clinical Drug Pipeline Developments & Deals by Genenta Science
Filters
Companies By Therapeutic Area
Details:
Temferon is based on ex-vivo gene transfer into autologous Tie2+ HSPCs to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages. It is being evaluated in phase 1/2 clinical trials for the treatment of uMGMT Glioblastoma Multiforme patients.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Temferon
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 08, 2024
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of Glioblastoma Multiforme.
Lead Product(s):
Temferon
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
July 28, 2023
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-α expression within cancers, which is investigated for the treatment of glioma.
Lead Product(s):
Temferon
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
June 29, 2023
Details:
The amended and restated license agreement reinforces Genenta's long-term strategic relationship with OSR, who contributes unique and valuable expertise to the development of cell-based therapies. Genenta has exclusive worldwide commercial rights to Temferon™.
Lead Product(s):
Undisclosed
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Ospedale San Raffaele
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Licensing Agreement
April 03, 2023
Details:
Temferon is a lenti-virus based hematopoietic stem progenitor cell immuno therapy enabling controlled and targeted interferon-alpha expression within cancers. Temferon modifies TEMs to release IFN-α inside tumors, rebuilding the immune system and counteracting cancer growth.
Lead Product(s):
Temferon
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 02, 2023
Details:
Ongoing trial of Temferon™ in glioblastoma multiforme patients who have an unmethylated MGMT gene promoter has escalated to next planned dose, on basis of no drug-limiting toxicities observed at lower doses, in previous three dose level cohorts.
Lead Product(s):
Temferon
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 04, 2022
Details:
Temferon, a lenti-virus based hematopoietic stem progenitor cell immuno-gene therapy enabling controlled and targeted interferon-α expression within cancers. Biologically delivered via engineered tumor-infiltrating monocytes, generates immune responses to any positive tumors.
Lead Product(s):
Lenti-virus Based Hematopoietic Stem Progenitor Cell Immuno-gene Therapy
Therapeutic Area: Oncology
Product Name: Temferon
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 20, 2022
Details:
Data from 15 treated patients to be presented are expected to provide initial evidence of successful engraftment of Temferon-derived cells and of on-target biological activity in patients with uMGMT-GBM.
Lead Product(s):
Temferon
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 09, 2022
Details:
Temferon™ is based on ex-vivo gene transfer into autologous hematopoietic stem/progenitor cells to deliver immunomodulatory molecules directly via tumor-infiltrating monocytes/macrophages.
Lead Product(s):
Hematopoietic Stem Progenitor Cell Immuno-gene Therapy
Therapeutic Area: Oncology
Product Name: Temferon
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 16, 2021
Details:
The ASGCT presentation shows that genetic markers of Genenta’s Temferon were detectable in tumor specimens from all four patients with progressive disease who underwent follow-on surgery.
Lead Product(s):
Hematopoietic stem progenitor cell immuno-gene therapy
Therapeutic Area: Oncology
Product Name: Temferon
Highest Development Status: Phase I/ Phase II
Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 14, 2021